ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Medicago and GlaxoSmithKline are reporting positive data from a Phase 2 clinical trial of a tobacco-grown COVID-19 vaccine. The vaccine, made by Medicago, is coupled with an adjuvant made by GSK. People in the trial developed neutralizing antibody levels 10 times as high as those in people who have had COVID-19, the companies say. Neutralizing antibodies can prevent SARS-CoV-2, the virus that causes COVID-19, from entering cells.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter